Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Clinical Trial
Share your love
Lotilaner Shows Promise for Treating Demodex Blepharitis
A team of investigators, led by Elizabeth Yeu, MD, from Virginia Eye Consultants in Norfolk, Virginia, reported the safety and efficacy of lotilaner ophthalmic solution, 0.25% (TP-03, Tarsus Pharmaceuticals Inc.), in treating Demodex blepharitis. Demodex mites are the most common…
Roche Halts Development of Diabetic Retinopathy Drug
Swiss-based pharmaceutical company Roche has announced the discontinuation of its oral diabetic retinopathy treatment, vicasinabin, after successfully completing Phase II clinical trials. In a recent presentation to investors, Roche confirmed its decision to halt further investment in vicasinabin, a promising…
EyePoint Launches VERONA Trial for EYP-1901 in DME
EyePoint Pharmaceuticals announced the dosing of the first patient in the VERONA clinical trial for their investigational therapy, EYP-1901, for the treatment of Diabetic Macular Edema (DME). EYP-1901, a sustained delivery therapy, incorporates vorolanib, a selective tyrosine kinase inhibitor, formulated…
Mantis Photonics Launches Eye Screening Crowdfunding
Mantis Photonics, at the forefront of space-inspired technology, announced the launch of a crowdfunding campaign for its seed round. This initiative, hosted on the Capital Cel platform, aims to fuel the development of Mantis Photonics’ noninvasive health screening technology using…
Promising Results for First Topical Treatment in DR
Exonate Ltd., a pioneering mRNA therapy company specializing in treatments for diabetic diseases, has announced that its lead ophthalmology asset, EXN407, successfully met prespecified endpoints in a phase Ib/IIa study for diabetic retinopathy and diabetic macular edema. During the trial,…
Vyjuvek Restores Vision in Teen with Rare Genetic Condition
Krystal Biotech’s topical gene therapy Vyjuvek (beremagene-geperpavec) has successfully restored the vision of a 13-year-old boy suffering from the rare genetic condition dystrophic epidermolysis bullosa (DEB), which scarred his eyes. The groundbreaking case, detailed in a recent publication in The…
Eyenovia’s Redwood City Facility Clears FDA Inspection
Eyenovia announced the successful completion of the FDA inspection for its facility in Redwood City, California, marking a significant milestone in the company’s manufacturing capabilities. This achievement signals the green light for the facility to engage in final assembly, packaging,…
Nicox and Kowa Strike Deal for NCX 470 in Japan
Nicox SA announced an agreement with Kowa, granting the latter exclusive rights in Japan for the development and commercialization of NCX 470, a promising nitric oxide (NO)-donating bimatoprost eye drop designed for reducing intraocular pressure (IOP) in individuals with glaucoma…
FDA Gives Green Light to OK-101 Trial for NCP Treatment
Okyo Pharma’s first investigational new drug (IND) application for OK-101 has been cleared by the U.S. Food and Drug Administration (FDA), marking a pivotal moment in the development of potential therapies for neuropathic corneal pain. Initially proposed as an open-label…
Low-Dose Atropine Eye Drops & Myopia Progression
According to the National Eye Institute (NEI), a trial conducted by the Pediatric Eye Disease Investigator Group (PEDIG) and funded by the NEI revealed that the use of low-dose atropine eye drops (concentration 0.01%) did not demonstrate superiority over a…